VXL — Vaxil Bio Cashflow Statement
0.000.00%
Last trade - 00:00- CA$0.52m
- CA$0.17m
- 42
- 63
- 13
- 32
Annual cashflow statement for Vaxil Bio, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -1.36 | -0.986 | -0.584 | -0.254 | -0.178 |
| Depreciation | |||||
| Non-Cash Items | 0.161 | 0.07 | 0.017 | 0.02 | -0.013 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.037 | -0.193 | -0.169 | -0.327 | -0.049 |
| Change in Accounts Receivable | |||||
| Change in Accounts Payable | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -1.1 | -1.08 | -0.734 | -0.561 | -0.24 |
| Other Investing Cash Flow Items | — | — | — | — | -0.25 |
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | — | — | — | — | -0.25 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 2.56 | 1.81 | 0 | — | — |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 1.43 | 0.731 | -0.731 | -0.572 | -0.49 |